Exelixis Inc (EXEL)

12.79
0.51 4.15
NASDAQ : Health Care
Prev Close 12.28
Open 12.44
Day Low/High 12.13 / 12.99
52 Wk Low/High 3.55 / 8.74
Volume 9.20M
Avg Volume 6.07M
Exchange NASDAQ
Shares Outstanding 230.33M
Market Cap 2.83B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist

Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral,...

'Mad Money' Lightning Round: Don't Sell Scripps

'Mad Money' Lightning Round: Don't Sell Scripps

Cramer says Fiserv is a winner and to pull the trigger on EPR Properties.

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters

Focus on finding stocks of high-quality companies at good prices, Cramer advises.

Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress

Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today provided an update on the timing of a key data presentation for cabozantinib at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11, 2016 in...

2 Bullish Stock Picks and 2 Stocks to Sell Short

2 Bullish Stock Picks and 2 Stocks to Sell Short

Here's a look at two stocks that are trending higher and two that are ripe for short-selling.

Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug

Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug

Exelixis (EXEL) said today that its renal cell carcinoma drug was approved by the European Commission, allowing it to be marketed in the European Union, among other areas.

European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission (EC) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular...

Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma

Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced the outcome from the first planned interim analysis of CELESTIAL, a randomized global phase 3 trial of cabozantinib compared with placebo in patients with advanced hepatocellular...

Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13

Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress

Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in...

Exelixis Stock Sees Short Interest Decrease By 29.7%

Exelixis Stock Sees Short Interest Decrease By 29.7%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 14,515,247 share decrease in total short interest for Exelixis Inc , to 34,290,608, a decrease of 29.74% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019

Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019

Exelixis, Inc. (NASDAQ:EXEL) today announced that it has called for redemption approximately $48.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Trade-Ideas: Exelixis (EXEL) Is Today's

Trade-Ideas: Exelixis (EXEL) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Exelixis (EXEL) Stock Is Soaring Today

Why Exelixis (EXEL) Stock Is Soaring Today

Exelixis (EXEL) stock was trading sharply higher this afternoon after reporting second-quarter financial results.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives, as well as commercial and clinical...

4 Tech and Biotech Stocks With Momentum to Watch

4 Tech and Biotech Stocks With Momentum to Watch

Here are four biotech and technology stocks showing strong technical momentum.

Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016

Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016

Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2016 financial results will be released on Wednesday, August 3, 2016 after the markets close.

Biotech Stock Mailbag: Heron, Exelixis

Biotech Stock Mailbag: Heron, Exelixis

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

Cramer is taking Honeywell over Boeing and is nervous about AIG.

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate

Today's Perilous Reversal Stock: Exelixis (EXEL)

Today's Perilous Reversal Stock: Exelixis (EXEL)

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) stock is higher in pre-market trading on Monday after the company announced positive trial data for its treatment for advanced kidney cancer.

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Regulatory News: Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™...

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™ (cabozantinib) tablets with...